Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Short Interest Update

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totaling 1,187,068 shares, an increase of 56.6% from the November 30th total of 758,068 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily volume of 577,313 shares, the days-to-cover ratio is presently 2.1 days. Based on an average daily volume of 577,313 shares, the days-to-cover ratio is presently 2.1 days. Approximately 0.2% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on FMS. Zacks Research cut shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Bank of America cut Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research report on Wednesday, October 15th. Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Finally, UBS Group cut Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research report on Wednesday, October 15th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $30.00.

Fresenius Medical Care AG & Co. KGaA Stock Up 0.1%

FMS opened at $24.09 on Monday. The firm’s fifty day moving average price is $24.36 and its 200 day moving average price is $25.55. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $22.05 and a 12-month high of $30.46. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 0.45.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. The business had revenue of $5.73 billion for the quarter, compared to analysts’ expectations of $4.72 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 7.42% and a net margin of 3.72%. On average, equities research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Institutional investors have recently made changes to their positions in the stock. CIBC Private Wealth Group LLC boosted its position in Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after purchasing an additional 1,103 shares during the period. Kestra Private Wealth Services LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 16.7% during the third quarter. Kestra Private Wealth Services LLC now owns 13,640 shares of the company’s stock worth $359,000 after acquiring an additional 1,955 shares during the period. Virtus Advisers LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 3rd quarter valued at $290,000. Qube Research & Technologies Ltd grew its position in Fresenius Medical Care AG & Co. KGaA by 11.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 223,222 shares of the company’s stock worth $5,877,000 after purchasing an additional 23,659 shares during the last quarter. Finally, Mariner LLC grew its position in Fresenius Medical Care AG & Co. KGaA by 3.4% during the third quarter. Mariner LLC now owns 49,661 shares of the company’s stock worth $1,308,000 after buying an additional 1,651 shares in the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.